Report final results from the Phase 3 NOTUS study of Dupixent in COPD
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 Aug 2023
- Due
- 30 Jun 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Company expects final results for the NOTUS study in mid-2024.”
What we found
Evidence strength A What the grades mean
The Q2 2024 10-Q, filed 2024-08-01, lists NOTUS results as reported in 2024 events to date, with presentation at the 2024 ATS conference. The exact reporting date is not stated.
-
A Regeneron Pharmaceuticals 10-Q filed 2024-08-01
“Reported that Phase 3 NOTUS trial in COPD with evidence of type 2 inflammation met its primary and key secondary endpoints; results presented at 2024 American Thoracic Society International Conference and published in NEJM” ✓ confirmed on the page
-
A Regeneron Pharmaceuticals 10-Q filed 2024-08-01
“Report results from ongoing Phase 3 trial in CSU (in biologic-naïve patients) (fourth quarter 2024)” ✓ confirmed on the page
Market reaction: the shares moved +5.3% against the S&P 500 over the three sessions around the disclosure (31 Jul 2024 to 5 Aug 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Final results from Phase 3 NOTUS study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-REGN-006345 · Corrections policy